Systemic correction of storage disease in MPS I NOD/SCID mice using the sleeping beauty transposon system

Department of Genetics, Cell Biology and Development, Center for Genome Engineering, University of Minnesota, Minneapolis, 55455, USA.
Molecular Therapy (Impact Factor: 6.23). 05/2009; 17(7):1136-44. DOI: 10.1038/mt.2009.87
Source: PubMed


The Sleeping Beauty (SB) transposon system is a nonviral vector that directs transgene integration into vertebrate genomes. We hydrodynamically delivered SB transposon plasmids encoding human alpha-L-iduronidase (hIDUA) at two DNA doses, with and without an SB transposase gene, to NOD.129(B6)-Prkdc(scid) IDUA(tm1Clk)/J mice. In transposon-treated, nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice with mucopolysaccharidosis type I (MPS I), plasma IDUA persisted for 18 weeks at levels up to several hundred-fold wild-type (WT) activity, depending on DNA dose and gender. IDUA activity was present in all examined somatic organs, as well as in the brain, and correlated with both glycosaminoglycan (GAG) reduction in these organs and level of expression in the liver, the target of transposon delivery. IDUA activity was higher in the treated males than in females. In females, omission of transposase source resulted in significantly lower IDUA levels and incomplete GAG reduction in some organs, confirming the positive effect of transposition on long-term IDUA expression and correction of the disease. The SB transposon system proved efficacious in correcting several clinical manifestations of MPS I in mice, including thickening of the zygomatic arch, hepatomegaly, and accumulation of foamy macrophages in bone marrow and synovium, implying potential effectiveness of this approach in treatment of human MPS I.

Download full-text


Available from: Lalitha R Belur, Oct 12, 2015
35 Reads
  • Source
    • "In another very elegant and simple method, naked DNA plasmids encoding a gene of interest are directly delivered into the liver by hydrodynamics-based transfection [14]. For stable gene expression, the transfection method has been coupled with the Sleeping Beauty transposon system, which mediates chromosomal integration of a transgene [15]–[17]. In this transgenic system, the expression cassette of a transgene is placed between two inverted terminal repeats (IRs), rendering the expression cassette transposable by Sleeping Beauty transposase. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Liver cancer is a complex multistep process requiring genetic alterations in multiple proto-oncogenes and tumor suppressor genes. Although hundreds of genes are known to play roles in hepatocarcinogenesis, oncogenic collaboration among these genes is still largely unknown. Here, we report a simple methodology by which oncogenic cooperation between cancer-related genes can be efficiently investigated in the liver. We developed various non-germline transgenic mouse models using hydrodynamics-based transfection which express HrasG12V, SmoM2, and a short-hairpin RNA down-regulating p53 (shp53) individually or in combination in the liver. In this transgenic system, firefly luciferase was co-expressed with the oncogenes as a reporter, allowing tumor growth in the liver to be monitored over time without an invasive procedure. Very strong bioluminescence imaging (BLI) signals were observed at 4 weeks post-hydrodynamic injection (PHI) in mice co-expressing HrasG12V and shp53, while only background signals were detected in other double or single transgenic groups until 30 weeks PHI. Consistent with the BLI data, tumors were observed in the HrasG12V plus shp53 group at 4 weeks PHI, while other transgenic groups failed to exhibit a hyperplastic nodule at 30 weeks PHI. In the HrasG12V plus shp53 transgenic group, BLI signals were well-correlated with actual tumor growth in the liver, confirming the versatility of BLI-based monitoring of tumor growth in this organ. The methodology described here is expected to accelerate and facilitate in vivo studies of the hepatocarcinogenic potential of cancer-related genes by means of oncogenic cooperation.
    PLoS ONE 03/2013; 8(3):e59869. DOI:10.1371/journal.pone.0059869 · 3.23 Impact Factor
  • Source
    • "Extensive efforts were made to enhance the transposition efficiency of SB, yielding a set of hyperactive transposase versions with SB100X being the most active transposase to date (31). The SB transposon system has been used to correct several genetic deficiencies in pre-clinical animal models including those for tyrosinemia type I (32), Huntington disease (33), hemophilia A and B (34–38), junctional epidermolysis bullosa (39), mucopolysaccharidosis (40,41), type 1 diabetes (42) and glioblastoma (43,44). In 2008 the National Institute of Health Recombinant DNA Advisory Committee (NIH RAC) approved the first-in-man gene therapy clinical trial that uses transposons. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The Sleeping Beauty (SB), piggyBac (PB) and Tol2 transposons are promising instruments for genome engineering. Integration site profiling of SB, PB and Tol2 in human cells showed that PB and Tol2 insertions were enriched in genes, whereas SB insertions were randomly distributed. We aimed to introduce a bias into the target site selection properties of the transposon systems by taking advantage of the locus-specific integration system of adeno-associated virus (AAV). The AAV Rep protein binds to Rep recognition sequences (RRSs) in the human genome, and mediates viral integration into nearby sites. A series of fusion constructs consisting of the N-terminal DNA-binding domain of Rep and the transposases or the N57 domain of SB were generated. A plasmid-based transposition assay showed that Rep/SB yielded a 15-fold enrichment of transposition at a particular site near a targeted RRS. Genome-wide insertion site analysis indicated that an approach based on interactions between the SB transposase and Rep/N57 enriched transgene insertions at RRSs. We also provide evidence of biased insertion of the PB and Tol2 transposons. This study provides a comparative insight into target site selection properties of transposons, as well as proof-of-principle for targeted chromosomal transposition by composite protein-protein and protein-DNA interactions.
    Nucleic Acids Research 04/2012; 40(14):6693-712. DOI:10.1093/nar/gks317 · 9.11 Impact Factor
  • Source
    • "Activity is expressed in units (nanomoles of substrate converted to product per hour) per mg protein, as determined by Bradford assay (BioRad). ß-glucuronidase (GUSB) activity was measured as previously described [19] from clarified tissue samples using 4MU-β-D-glucuronide (Sigma) as substrate. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Here we provide the first evidence that therapeutic levels of a lysosomal enzyme can bypass the blood-brain barrier following intranasal administration. α-L-iduronidase (IDUA) activity was detected throughout the brains of IDUA-deficient mice following a single intranasal treatment with concentrated Aldurazyme® (laronidase) and was also detected after intranasal treatment with an adeno-associated virus (AAV) vector expressing human IDUA. These results suggest that intranasal routes of delivery may be efficacious in the treatment of lysosomal storage disorders.
    Molecular Genetics and Metabolism 02/2012; 106(1):131-4. DOI:10.1016/j.ymgme.2012.02.006 · 2.63 Impact Factor
Show more